First Us Fda approval of Car-T therapy hikes expectations for Korean biotech ventures


The US Food and Drug Administration's first approval of a CAR-T cell therapy is raising market expectations for South Korean biotech ventures that are currently working to develop similar cellular immunotherapy drugs for cancer. On Aug. 30, the US drug regulator approved Novartis' Kymriah, a CAR-T cell therapy that genetically alters a patient's own immune cells into a "living drug" that is trained to recognize and attack cancer cells in the blood.



from Biotech News